The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings
F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on F-FDG PET/CT scans. Because Ga-radiolabeled fibroblast activation protein inhibi...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2022-06, Vol.63 (6), p.875-881 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 881 |
|---|---|
| container_issue | 6 |
| container_start_page | 875 |
| container_title | Journal of Nuclear Medicine |
| container_volume | 63 |
| creator | Gu, Bingxin Xu, Xiaoping Zhang, Ji Ou, Xiaomin Xia, Zuguang Guan, Qing Hu, Silong Yang, Zhongyi Song, Shaoli |
| description | F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on
F-FDG PET/CT scans. Because
Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed to evaluate the performance of
Ga-FAPI PET/CT for detecting the primary tumor in HNCUP patients with negative
F-FDG findings.
Eighteen patients (16 men and 2 women; median age, 55 y; age range, 24-72 y) with negative
F-FDG findings were enrolled in this study. All patients underwent
F-FDG and
Ga-FAPI PET/CT within 1 wk. Biopsy and histopathologic examinations were performed in the sites with positive
Ga-FAPI PET/CT findings.
Ga-FAPI PET/CT detected the primary tumor in 7 of 18 patients (38.89%). Among these 7 patients, primary tumor sites included the nasopharynx (
= 1), palatine tonsil (
= 2), submandibular gland (
= 2), and hypopharynx (
= 2). The primary tumors showed moderate to intensive uptake of
Ga-FAPI (mean SUV
, 8.79; range, 2.60-16.50) and excellent tumor-to-contralateral normal-tissue ratio (mean SUV
ratio, 4.50; range, 2.17-8.21). In lesion-based analysis, 65 lymph nodes and 17 bone metastatic lesions were identified. The mean SUV
of lymph node metastases was 9.05 ± 5.29 for
F-FDG and 9.08 ± 4.69 for
Ga-FAPI (
= 0.975); the mean SUV
of bone metastases was 8.11 ± 3.00 for
F-FDG and 6.96 ± 5.87 for
Ga-FAPI (
= 0.478). The mean tumor-to-background ratios of lymph node and bone metastases were 10.65 ± 6.59 versus 12.80 ± 8.11 (
= 0.100) and 9.08 ± 3.35 versus 9.14 ± 8.40 (
= 0.976), respectively.
We present the first evidence, to our knowledge, of a diagnostic role of
Ga-FAPI PET/CT in HNCUP. Our study demonstrated that
Ga-FAPI PET/CT has the potential to improve the detection rate of primary tumor in HNCUP patients with negative
F-FDG findings. Moreover,
Ga-FAPI had a performance in assessing metastases similar to that of
F-FDG. |
| doi_str_mv | 10.2967/jnumed.121.262790 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2967_jnumed_121_262790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34593594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1134-ee271ec6de1e8b036ae7721062e81283ca09717de715b01436be3d9273ae4b543</originalsourceid><addsrcrecordid>eNo1kM1OwkAUhSdGI4g-gBszL1CYO9P56ZJUCiQGWRS3zbRzgfIzkBYkLnx3SyqruzjnO7n5CHkF1ueR0oONP-_R9YFDnyuuI3ZHuiCFDKRS-p50GSgIpGSyQ57qesMYU8aYR9IRoYyEjMIu-U3XSIfOoaNfdndGelhSZejYBslwPqXzUTqIU1p6OrenEv2pppfytKYTtI5a7-gMiy2NrS-wuqILv_WHS9Ouyr2tftoyGJoEyfs4mOGqWflGmpTelX5VP5OHpd3V-PJ_e2SRjNJ4Enx8jqfx8CMoAEQYIHINWCiHgCZnQlnUmgNTHA1wIwrLIg3aoQaZMwiFylG4iGthMcxlKHoE2t2iOtR1hcvs2D6YAcuuKrNWZdaozFqVDfPWMsdzfo1uxM2d-AM5DW1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gu, Bingxin ; Xu, Xiaoping ; Zhang, Ji ; Ou, Xiaomin ; Xia, Zuguang ; Guan, Qing ; Hu, Silong ; Yang, Zhongyi ; Song, Shaoli</creator><creatorcontrib>Gu, Bingxin ; Xu, Xiaoping ; Zhang, Ji ; Ou, Xiaomin ; Xia, Zuguang ; Guan, Qing ; Hu, Silong ; Yang, Zhongyi ; Song, Shaoli</creatorcontrib><description>F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on
F-FDG PET/CT scans. Because
Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed to evaluate the performance of
Ga-FAPI PET/CT for detecting the primary tumor in HNCUP patients with negative
F-FDG findings.
Eighteen patients (16 men and 2 women; median age, 55 y; age range, 24-72 y) with negative
F-FDG findings were enrolled in this study. All patients underwent
F-FDG and
Ga-FAPI PET/CT within 1 wk. Biopsy and histopathologic examinations were performed in the sites with positive
Ga-FAPI PET/CT findings.
Ga-FAPI PET/CT detected the primary tumor in 7 of 18 patients (38.89%). Among these 7 patients, primary tumor sites included the nasopharynx (
= 1), palatine tonsil (
= 2), submandibular gland (
= 2), and hypopharynx (
= 2). The primary tumors showed moderate to intensive uptake of
Ga-FAPI (mean SUV
, 8.79; range, 2.60-16.50) and excellent tumor-to-contralateral normal-tissue ratio (mean SUV
ratio, 4.50; range, 2.17-8.21). In lesion-based analysis, 65 lymph nodes and 17 bone metastatic lesions were identified. The mean SUV
of lymph node metastases was 9.05 ± 5.29 for
F-FDG and 9.08 ± 4.69 for
Ga-FAPI (
= 0.975); the mean SUV
of bone metastases was 8.11 ± 3.00 for
F-FDG and 6.96 ± 5.87 for
Ga-FAPI (
= 0.478). The mean tumor-to-background ratios of lymph node and bone metastases were 10.65 ± 6.59 versus 12.80 ± 8.11 (
= 0.100) and 9.08 ± 3.35 versus 9.14 ± 8.40 (
= 0.976), respectively.
We present the first evidence, to our knowledge, of a diagnostic role of
Ga-FAPI PET/CT in HNCUP. Our study demonstrated that
Ga-FAPI PET/CT has the potential to improve the detection rate of primary tumor in HNCUP patients with negative
F-FDG findings. Moreover,
Ga-FAPI had a performance in assessing metastases similar to that of
F-FDG.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.121.262790</identifier><identifier>PMID: 34593594</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Bone Diseases ; Female ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Head and Neck Neoplasms - diagnostic imaging ; Humans ; Male ; Middle Aged ; Neoplasms, Unknown Primary ; Positron Emission Tomography Computed Tomography ; Young Adult</subject><ispartof>Journal of Nuclear Medicine, 2022-06, Vol.63 (6), p.875-881</ispartof><rights>2022 by the Society of Nuclear Medicine and Molecular Imaging.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1134-ee271ec6de1e8b036ae7721062e81283ca09717de715b01436be3d9273ae4b543</citedby><cites>FETCH-LOGICAL-c1134-ee271ec6de1e8b036ae7721062e81283ca09717de715b01436be3d9273ae4b543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34593594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Bingxin</creatorcontrib><creatorcontrib>Xu, Xiaoping</creatorcontrib><creatorcontrib>Zhang, Ji</creatorcontrib><creatorcontrib>Ou, Xiaomin</creatorcontrib><creatorcontrib>Xia, Zuguang</creatorcontrib><creatorcontrib>Guan, Qing</creatorcontrib><creatorcontrib>Hu, Silong</creatorcontrib><creatorcontrib>Yang, Zhongyi</creatorcontrib><creatorcontrib>Song, Shaoli</creatorcontrib><title>The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on
F-FDG PET/CT scans. Because
Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed to evaluate the performance of
Ga-FAPI PET/CT for detecting the primary tumor in HNCUP patients with negative
F-FDG findings.
Eighteen patients (16 men and 2 women; median age, 55 y; age range, 24-72 y) with negative
F-FDG findings were enrolled in this study. All patients underwent
F-FDG and
Ga-FAPI PET/CT within 1 wk. Biopsy and histopathologic examinations were performed in the sites with positive
Ga-FAPI PET/CT findings.
Ga-FAPI PET/CT detected the primary tumor in 7 of 18 patients (38.89%). Among these 7 patients, primary tumor sites included the nasopharynx (
= 1), palatine tonsil (
= 2), submandibular gland (
= 2), and hypopharynx (
= 2). The primary tumors showed moderate to intensive uptake of
Ga-FAPI (mean SUV
, 8.79; range, 2.60-16.50) and excellent tumor-to-contralateral normal-tissue ratio (mean SUV
ratio, 4.50; range, 2.17-8.21). In lesion-based analysis, 65 lymph nodes and 17 bone metastatic lesions were identified. The mean SUV
of lymph node metastases was 9.05 ± 5.29 for
F-FDG and 9.08 ± 4.69 for
Ga-FAPI (
= 0.975); the mean SUV
of bone metastases was 8.11 ± 3.00 for
F-FDG and 6.96 ± 5.87 for
Ga-FAPI (
= 0.478). The mean tumor-to-background ratios of lymph node and bone metastases were 10.65 ± 6.59 versus 12.80 ± 8.11 (
= 0.100) and 9.08 ± 3.35 versus 9.14 ± 8.40 (
= 0.976), respectively.
We present the first evidence, to our knowledge, of a diagnostic role of
Ga-FAPI PET/CT in HNCUP. Our study demonstrated that
Ga-FAPI PET/CT has the potential to improve the detection rate of primary tumor in HNCUP patients with negative
F-FDG findings. Moreover,
Ga-FAPI had a performance in assessing metastases similar to that of
F-FDG.</description><subject>Adult</subject><subject>Aged</subject><subject>Bone Diseases</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Gallium Radioisotopes</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms, Unknown Primary</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Young Adult</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1OwkAUhSdGI4g-gBszL1CYO9P56ZJUCiQGWRS3zbRzgfIzkBYkLnx3SyqruzjnO7n5CHkF1ueR0oONP-_R9YFDnyuuI3ZHuiCFDKRS-p50GSgIpGSyQ57qesMYU8aYR9IRoYyEjMIu-U3XSIfOoaNfdndGelhSZejYBslwPqXzUTqIU1p6OrenEv2pppfytKYTtI5a7-gMiy2NrS-wuqILv_WHS9Ouyr2tftoyGJoEyfs4mOGqWflGmpTelX5VP5OHpd3V-PJ_e2SRjNJ4Enx8jqfx8CMoAEQYIHINWCiHgCZnQlnUmgNTHA1wIwrLIg3aoQaZMwiFylG4iGthMcxlKHoE2t2iOtR1hcvs2D6YAcuuKrNWZdaozFqVDfPWMsdzfo1uxM2d-AM5DW1w</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Gu, Bingxin</creator><creator>Xu, Xiaoping</creator><creator>Zhang, Ji</creator><creator>Ou, Xiaomin</creator><creator>Xia, Zuguang</creator><creator>Guan, Qing</creator><creator>Hu, Silong</creator><creator>Yang, Zhongyi</creator><creator>Song, Shaoli</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202206</creationdate><title>The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings</title><author>Gu, Bingxin ; Xu, Xiaoping ; Zhang, Ji ; Ou, Xiaomin ; Xia, Zuguang ; Guan, Qing ; Hu, Silong ; Yang, Zhongyi ; Song, Shaoli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1134-ee271ec6de1e8b036ae7721062e81283ca09717de715b01436be3d9273ae4b543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bone Diseases</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Gallium Radioisotopes</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms, Unknown Primary</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Bingxin</creatorcontrib><creatorcontrib>Xu, Xiaoping</creatorcontrib><creatorcontrib>Zhang, Ji</creatorcontrib><creatorcontrib>Ou, Xiaomin</creatorcontrib><creatorcontrib>Xia, Zuguang</creatorcontrib><creatorcontrib>Guan, Qing</creatorcontrib><creatorcontrib>Hu, Silong</creatorcontrib><creatorcontrib>Yang, Zhongyi</creatorcontrib><creatorcontrib>Song, Shaoli</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Bingxin</au><au>Xu, Xiaoping</au><au>Zhang, Ji</au><au>Ou, Xiaomin</au><au>Xia, Zuguang</au><au>Guan, Qing</au><au>Hu, Silong</au><au>Yang, Zhongyi</au><au>Song, Shaoli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2022-06</date><risdate>2022</risdate><volume>63</volume><issue>6</issue><spage>875</spage><epage>881</epage><pages>875-881</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on
F-FDG PET/CT scans. Because
Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed to evaluate the performance of
Ga-FAPI PET/CT for detecting the primary tumor in HNCUP patients with negative
F-FDG findings.
Eighteen patients (16 men and 2 women; median age, 55 y; age range, 24-72 y) with negative
F-FDG findings were enrolled in this study. All patients underwent
F-FDG and
Ga-FAPI PET/CT within 1 wk. Biopsy and histopathologic examinations were performed in the sites with positive
Ga-FAPI PET/CT findings.
Ga-FAPI PET/CT detected the primary tumor in 7 of 18 patients (38.89%). Among these 7 patients, primary tumor sites included the nasopharynx (
= 1), palatine tonsil (
= 2), submandibular gland (
= 2), and hypopharynx (
= 2). The primary tumors showed moderate to intensive uptake of
Ga-FAPI (mean SUV
, 8.79; range, 2.60-16.50) and excellent tumor-to-contralateral normal-tissue ratio (mean SUV
ratio, 4.50; range, 2.17-8.21). In lesion-based analysis, 65 lymph nodes and 17 bone metastatic lesions were identified. The mean SUV
of lymph node metastases was 9.05 ± 5.29 for
F-FDG and 9.08 ± 4.69 for
Ga-FAPI (
= 0.975); the mean SUV
of bone metastases was 8.11 ± 3.00 for
F-FDG and 6.96 ± 5.87 for
Ga-FAPI (
= 0.478). The mean tumor-to-background ratios of lymph node and bone metastases were 10.65 ± 6.59 versus 12.80 ± 8.11 (
= 0.100) and 9.08 ± 3.35 versus 9.14 ± 8.40 (
= 0.976), respectively.
We present the first evidence, to our knowledge, of a diagnostic role of
Ga-FAPI PET/CT in HNCUP. Our study demonstrated that
Ga-FAPI PET/CT has the potential to improve the detection rate of primary tumor in HNCUP patients with negative
F-FDG findings. Moreover,
Ga-FAPI had a performance in assessing metastases similar to that of
F-FDG.</abstract><cop>United States</cop><pmid>34593594</pmid><doi>10.2967/jnumed.121.262790</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2022-06, Vol.63 (6), p.875-881 |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_crossref_primary_10_2967_jnumed_121_262790 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Bone Diseases Female Fluorodeoxyglucose F18 Gallium Radioisotopes Head and Neck Neoplasms - diagnostic imaging Humans Male Middle Aged Neoplasms, Unknown Primary Positron Emission Tomography Computed Tomography Young Adult |
| title | The Added Value of 68 Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18 F-FDG-Negative Findings |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A48%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Added%20Value%20of%2068%20Ga-FAPI%20PET/CT%20in%20Patients%20with%20Head%20and%20Neck%20Cancer%20of%20Unknown%20Primary%20with%2018%20F-FDG-Negative%20Findings&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Gu,%20Bingxin&rft.date=2022-06&rft.volume=63&rft.issue=6&rft.spage=875&rft.epage=881&rft.pages=875-881&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.121.262790&rft_dat=%3Cpubmed_cross%3E34593594%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34593594&rfr_iscdi=true |